TPI 1100

Drug Profile

TPI 1100

Alternative Names: PD 3 project; PXS TPI 1100; TPI-PD3 project

Latest Information Update: 01 Apr 2011

Price : $50

At a glance

  • Originator Topigen Pharmaceuticals
  • Developer Pharmaxis; Topigen Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Phosphoric diester hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Chronic obstructive pulmonary disease

Most Recent Events

  • 09 Feb 2010 Topigen Pharmaceuticals has been acquired and merged into Pharmaxis
  • 15 Jul 2008 Phase-I clinical trials in Chronic obstructive pulmonary disease in North America (Inhalation)
  • 16 Dec 2004 Preclinical trials in Chronic obstructive pulmonary disease in Canada (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top